UB Paderborn / Katalog / Suche / in CDI

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-04, Vol.325 (14), p.1403

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-01, Vol.327 (2), p.138

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

The Lancet (British edition), 2021-05, Vol.397 (10286), p.1736-1748

2021

Link zum Volltext

Verfügbarkeit prüfen

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-08, Vol.402 (10403), p.705-719

2023

Link zum Volltext

Verfügbarkeit prüfen

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Diabetes, obesity & metabolism, 2023-02, Vol.25 (2), p.468-478

2023

Link zum Volltext

Verfügbarkeit prüfen

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Postgraduate medicine, 2022, Vol.134 (1), p.14-19

2022

Link zum Volltext

Verfügbarkeit prüfen

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.94-105

2022

Link zum Volltext

Verfügbarkeit prüfen

Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program

Postgraduate medicine, 2022-04, Vol.134 (sup1), p.28-36

2022

Link zum Volltext

Verfügbarkeit prüfen

Weight History in Clinical Practice: The State of the Science and Future Directions

Obesity (Silver Spring, Md.), 2020-01, Vol.28 (1), p.9-17

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes

Obesity (Silver Spring, Md.), 2016-11, Vol.24 (11), p.2269-2277

2016

Link zum Volltext

Verfügbarkeit prüfen

Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes

International Journal of Obesity, 2020-05, Vol.44 (5), p.990-998

2020

Link zum Volltext

Verfügbarkeit prüfen

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

EClinicalMedicine, 2023-01, Vol.55, p.101737-101737, Article 101737

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial

Journal of diabetes and its complications, 2017-05, Vol.31 (5), p.891-897

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-04, Vol.325 (14), p.1414

2021

Link zum Volltext

Verfügbarkeit prüfen

A review of topiramate and phentermine: a combined therapeutic approach for obesity

Clinical lipidology, 2012-02, Vol.7 (1), p.13-25

2012

Link zum Volltext

Verfügbarkeit prüfen

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY: EXECUTIVE SUMMARY

Endocrine practice, 2016-07, Vol.22 (7), p.842

2016

Link zum Volltext

Verfügbarkeit prüfen

TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.1626-1626

2021

Link zum Volltext

Verfügbarkeit prüfen

CONTINUED TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 4 TRIAL

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.1608-1608

2021

Link zum Volltext

Verfügbarkeit prüfen

IMPROVEMENT OF THE 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK WITH ONCE-WEEKLY SEMAGLUTIDE 2.4 MG IN ADULTS WITH OVERWEIGHT OR OBESITY - POST-HOC ANALYSIS OF THE STEP 1 TRIAL

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.1606-1606

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment With Once-weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity and Type 2 Diabetes: STEP 2 Post Hoc Analysis

Canadian journal of diabetes, 2022-11, Vol.46 (7), p.S27-S28

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trialsResearch in context

EClinicalMedicine, 2023-01, Vol.55, p.101737

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management

Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A26-A27

2021

Link zum Volltext

Verfügbarkeit prüfen

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A63-A64

2021

Link zum Volltext

Verfügbarkeit prüfen

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITYEXECUTIVE SUMMARYComplete Guidelines available at https://www.aace.com/publications/guidelines

Endocrine practice, 2016-07, Vol.22 (7), p.842-884

2016

Link zum Volltext

Verfügbarkeit prüfen

The Proto-oncoprotein Brx Activates Estrogen Receptor β by a p38 Mitogen-activated Protein Kinase Pathway

The Journal of biological chemistry, 2001-12, Vol.276 (50), p.46792-46797

2001

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program

Weight History in Clinical Practice: The State of the Science and Future Directions

Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes

Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

A review of topiramate and phentermine: a combined therapeutic approach for obesity

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY: EXECUTIVE SUMMARY

TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL

CONTINUED TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 4 TRIAL

IMPROVEMENT OF THE 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK WITH ONCE-WEEKLY SEMAGLUTIDE 2.4 MG IN ADULTS WITH OVERWEIGHT OR OBESITY - POST-HOC ANALYSIS OF THE STEP 1 TRIAL

Treatment With Once-weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity and Type 2 Diabetes: STEP 2 Post Hoc Analysis

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trialsResearch in context

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITYEXECUTIVE SUMMARYComplete Guidelines available at https://www.aace.com/publications/guidelines

The Proto-oncoprotein Brx Activates Estrogen Receptor β by a p38 Mitogen-activated Protein Kinase Pathway

Suchergebnisse filtern